ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)
1 story in the last 7 days
The latest anxiety news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks anxiety across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.

Definium Therapeutics' Phase III Voyage trial showed its LSD drug DT120 significantly reduced anxiety in 214 adults with generalized anxiety disorder versus placebo. The FDA granted DT120 breakthrough therapy designation. Definium, formerly MindMed, is running further Phase III studies for depression and anxiety.
Summaries by ByteBrief